Biocon Shares Rise on Indian Approval for Liraglutide Diabetes Treatment

Biocon Limited, a global biopharmaceutical firm, has secured regulatory approval in India for its Liraglutide drug substance. Its subsidiary, Biocon Pharma Limited, has also obtained clearance for the Liraglutide drug product (6 mg/ml pre-filled pen and cartridge). This approval comes via CDSCO’s “101 route,” which recognises approvals from trusted global regulatory agencies. The drug is a generic version of Victoza®, used to manage Type 2 Diabetes in adults and children aged 10 and above, in conjunction with a healthy diet and exercise regimen.

Significance and Market Potential

Siddharth Mittal, CEO and MD of Biocon, highlighted this milestone as Biocon’s first fully integrated GLP-1 product in India, marking a critical step in improving access to diabetes treatment. With India housing over 77 million diabetic patients and numbers projected to rise, the approval supports Biocon’s mission to deliver cost-effective, life-saving treatments. The company plans a swift product launch in collaboration with commercial partners and aims to establish a strong foothold in the GLP-1 therapy market, which holds significant growth prospects.

Product and Company Background

Liraglutide is a synthetic version of the GLP-1 peptide, administered as a once-daily injection. It has received approvals in the EU, US, and for paediatric use since 2009. GLP-1 drugs regulate blood sugar, support weight loss, and improve insulin response. Biocon, listed since 2004, specialises in developing advanced therapies for chronic diseases like diabetes and cancer. The company operates across major markets including India, the US, and Europe, offering both biosimilars and innovative biologics.

Read More: Best Pharma Stocks in June 2025!

Biocon Share Price Performance 

As of June 03, 2025, at 12:50 PM, Biocon share price is trading at ₹338.45 per share, reflecting a surge of 1.33% from the previous day's closing price. Over the past month, the stock has surged by 0.76%. The stock's 52-week high stands at ₹404.70 per share, while its low is ₹269.55 per share.

Conclusion 

Biocon’s approval for Liraglutide marks a significant stride in enhancing diabetes care in India, reinforcing its commitment to accessible and innovative healthcare solutions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.